ABSTRACT 43 44
laboratories or laboratory networks, to survey the presence of specific microbial agents known 48 to constitute a threat to public health in a given population. This monitoring activity is 49 commonly based on a representative fraction of the microbiology laboratories nationally 50
reporting to a single central reference point. However in recent years a number of clinical 51 microbiology laboratories (CML) have undergone a process of consolidation involving a shift 52 towards laboratory amalgamation and closer real-time informational linkage. This report aims 53
to investigate whether such merging activities might have a potential impact on infectious 54 diseases surveillance. Influenza data was used from Belgian public health surveillance 2014-55 2017, to evaluate whether national infection trends could be estimated equally as effectively 56 from only just one centralised CML serving the wider Brussels area (LHUB-ULB). The 57 overall comparison reveals that there is a close correlation and representativeness of the 58 LHUB-ULB data to the national and international data for the same time periods, both on 59 epidemiological and molecular grounds. Notably, the effectiveness of the LHUB-ULB 60 surveillance remains partially subject to local regional variations. These results illustrate that 61 centralised CML-derived data are not only credible but also advantageous to use for future 62 surveillance and prediction purposes, especially for automatic detection systems that might 63 include multiple layers of information and timely implementation of control strategies. 64
INTRODUCTION 66
In parallel, the rationalisation of public health costs has led to the development of novel 101 strategies for laboratories' cost containment. In this perspective, a number of CMLs have 102 undergone a process of consolidation involving a shift towards laboratory amalgamation and 103 closer real-time informational linkage. Through this consolidation activity, an operational 104 model has emerged with large centralized clinical laboratories performing on one central 105 platform and one or several distal laboratories dealing locally only with urgent analyses. The 106 increasing centralisation of diagnostic services over a large geographical region has given rise 107 to the concept of "microbiology laboratories network" (16). The reduction in the number of 108 small clinical laboratories and the aggregation of the remaining ones, may condition the 109 ability to detect epidemiological changes. The sensitivity and representativeness of national 110 surveillance systems should be therefore carefully monitored using coverage measures which 111 indicate the proportion of the target population included within the surveillance system (15). 112
113
It is conceivable that the consolidated CMLs could become a cornerstone of public health 114 models in the near future akin to the regional healthcare hospital networks with interactive 115 surveillance for AMR control in France and cross-border regions (17). Due to the adoption of 116 a 24/7 working scheme and improved automation, consolidated CMLs are also able to analyse 117 a large influx of samples in the context of an outbreak investigation. In addition to the volume 118 capacities and the large range of diagnostic tools, the ability of consolidated CMLs to access 119 multiple different partners, geographies and clinical specialities can enhance their capabilities 120 to provide advanced systems for disease surveillance and early recognition. 121
122
As there is the potential that such CMLs merging might have a consequence on infectious 123 diseases surveillance, we used the availability of Influenza data to evaluate whether influenza 124 infection trends could be estimated effectively from only one CML serving the Brussels area. 125
The obtained data was compared to the available laboratory surveillance data provided by the 126 directorate Epidemiology and public health of Sciensano in Belgium for the same time period. 
Microbiology methods 175
To better assess the input of the LHUB-ULB as early warning lab for molecular surveillance, The representativeness of the LHUB-ULB in terms of molecular epidemiology was assessed 233
by the phylogenetic analysis of the sequenced isolates (Figure 4) . The LHUB-ULB derived 234
Hemagglutinin (HA) sequences (n=39) were compared to all sequences available from 235 GISAID from Belgium for the same time period (n=17) and an equivalent number of 236 sequences from the United Kingdom (n=56), France (n =126) and the Netherland (n =36). 237
Most of the LHUB-ULB samples constitute distinct phylogenetic clusters, co-located with 238
other samples with Belgium as a place of origin, within a background of seasonal Influenza A 239 phylogeny. Preliminary results show that no significant genomic differences were observed 240 within the LHUB-ULB samples or against deposited genomes from the same location and 241 time period in Belgium, the Netherlands and France. However, most LHUB-ULB derived 242 sequences form clusters distinct to the UK-derived samples. This observation would require 243 larger sample numbers than the ones currently available and to be repeated for a number of 244 seasons in order to be further validated. Figure 4b shows HA sequence analyses, though the 245 LHUB-ULB samples did have the Neuraminidase (NA) genomic information available due to 246 the whole genome sequencing, the availability of NA sequences in the public databases from 247 the same samples was almost entirely unavailable. The use of data from large CMLs may file this gap that the privatization of the laboratory 276 medicine may beget. In this study, the handling of the flu data from the LHUB-ULB reveals 277 its attractive features that can facilitate an early detection of seasonal influenza epidemics. 278
These results illustrate that data are not only credible but also advantageous to use for 279 surveillance and prediction purposes, especially for an automatic detection system. Despite, 280 the LHUB-ULB catchment area represents a small geographical area; its representativeness 281 for the nation-wide data is striking. In the future, the extent of representation will be further 282 improved when data are collected from more consolidated laboratories. 283
In addition, this study confirms the lack of covering by BSLN in some municipalities located 285 in Flanders or in Wallonia (15). In our study, the LHUB-ULB represented each year 100% of 286 the notification in several municipalities located in these regions. The use of laboratory 287 In this frame, the use of high-throughput whole genome sequencing platforms available in 297
large CMLs network such as met in the LHUB-ULB demonstrates its potential for molecular 298 epidemiological surveillance. Because, early detection of epidemics is a key element to 299 prevent loss of (quality of) life and its economic and material impact, such molecular 300 surveillance would gain in efficiency through automated real-time monitoring and reporting to 301 public health authorities from the regional to the European levels. Other European countries 302 have started demonstrating a clinical benefit from such data collected initiatives, as is the case 303 in the UK at the National Mycobacterial Reference Service in Birmingham (26) and at UCLH 304 with the integration of near real-time, whole genome sequencing utilised for the purposes of 305 HIV and Influenza surveillance (19, 27) . 306
307
However the availability of new microbial typing and detection techniques and culture-308 independent diagnostic methods, brings about a fundamental change in the way data has to be 309 handled. These approaches are high-throughput and data-rich and create systematic stresses in 310 the collection, analyses and safe handling of the generated data (28). For example one current 311 obstacle towards clinical translation is that most algorithms in use need some programming 312 expertise, together with specialized servers to handle and store all of the data. The generation 313 of user-friendly informatics tools to effectively analyse high-throughput genomic data will be 314 essential to the successful clinical application of genomic technology. In addition there are 315 systemic aspects that also need to be addressed, such as the number of additional molecular or 316 genomic testing parameters, regardless of the method, which can be supported routinely by 317 the existing electronic health records that provide the architectural framework. These aspectscan include the ordering of the test, the receiving of a document that summarizes the clinical 319 interpretation, and storage of the interpretation (29). The integration of molecular genetic data 320 to clinical and/or epidemiological data creates a challenge that requires interactive, 321 information-sharing workspaces rather than uni-directional centralised reporting, such as 322 those deployed in the TYPENED approach (30). 
